Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

iRadimed Sees Q2 Adj EPS $0.41-$0.44 vs $0.43 Est; Sees Sales $19.700M-$19.900M vs $19.81M Est

Author: Benzinga Newsdesk | May 05, 2025 06:09am
iRadimed (NASDAQ:IRMD) is looking for Q2 Adj EPS of $0.41-$0.44 vs $0.43 analyst estimate. sees sales of $19.700 million-$19.900 million vs $19.81 million analyst estimate.

Posted In: IRMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist